Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$17.66 USD

17.66
1,533,637

+0.46 (2.67%)

Updated Nov 8, 2024 04:00 PM ET

Pre-Market: $17.80 +0.14 (0.79%) 8:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate

by Zacks Equity Research

Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.

    Kite Pharma at New 52-Week High: What's Driving the Stock?

    by Zacks Equity Research

    Kite Pharma (KITE) shares hit a new 52-week high as the company's CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. It has also filed regulatory application for the candidate in the EU.

      Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data

      by Zacks Equity Research

      Ultragenyx (RARE) plans to discontinue further clinical development of Ace-ER after posting discouraging data from a phase III study that evaluated the candidate on patients with GNE Myopathy.

        Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer

        by Zacks Equity Research

        Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.

          FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa

          by Zacks Equity Research

          FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.

            Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

            by Zacks Equity Research

            Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

              Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More

              by Zacks Equity Research

              A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.

                Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?

                by Zacks Equity Research

                ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.

                  Minerva On Track to Initiate Phase III Schizophrenia Study

                  by Zacks Equity Research

                  Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.

                    What's in the Cards for ACADIA (ACAD) this Earnings Season?

                    by Zacks Equity Research

                    ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.

                      ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?

                      by Zacks Equity Research

                      ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.

                        ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint

                        by Zacks Equity Research

                        ACADIA Pharmaceuticals Inc. (ACAD) announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint.